Skandinaviska Enskilda Banken Ab (Publ) Madrigal Pharmaceuticals, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $24.3 Billion
- Q3 2025
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 18,363 shares of MDGL stock, worth $9.72 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
18,363
Previous 3,978
361.61%
Holding current value
$9.72 Million
Previous $1.2 Million
600.08%
% of portfolio
0.03%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding MDGL
# of Institutions
405Shares Held
23.1MCall Options Held
665KPut Options Held
514K-
Baker Bros. Advisors LP New York, NY2.14MShares$1.13 Billion8.0% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$1.06 Billion12.22% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny1.91MShares$1.01 Billion31.28% of portfolio
-
Janus Henderson Group PLC London, X01.84MShares$975 Million0.41% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.83MShares$970 Million11.49% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $9.05B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...